|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0013089,
umls-concept:C0018787,
umls-concept:C0043210,
umls-concept:C0144576,
umls-concept:C0205195,
umls-concept:C0278488,
umls-concept:C0574032,
umls-concept:C1280500,
umls-concept:C1511237,
umls-concept:C1550436,
umls-concept:C1705509,
umls-concept:C2603343
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
1995-12-15
|
|
pubmed:abstractText |
To define the maximum-tolerated dose (MTD) and better tolerated sequence of paclitaxel by 3-hour infusion plus bolus doxorubicin (DOX) and to evaluate antitumor efficacy.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
13
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
N
|
|
pubmed:pagination |
2688-99
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:7595726-Adult,
pubmed-meshheading:7595726-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:7595726-Breast Neoplasms,
pubmed-meshheading:7595726-Chi-Square Distribution,
pubmed-meshheading:7595726-Doxorubicin,
pubmed-meshheading:7595726-Drug Administration Schedule,
pubmed-meshheading:7595726-Female,
pubmed-meshheading:7595726-Heart,
pubmed-meshheading:7595726-Heart Failure,
pubmed-meshheading:7595726-Humans,
pubmed-meshheading:7595726-Infusions, Intravenous,
pubmed-meshheading:7595726-Middle Aged,
pubmed-meshheading:7595726-Neoplasm Metastasis,
pubmed-meshheading:7595726-Neutropenia,
pubmed-meshheading:7595726-Paclitaxel,
pubmed-meshheading:7595726-Peripheral Nervous System Diseases,
pubmed-meshheading:7595726-Remission Induction
|
|
pubmed:year |
1995
|
|
pubmed:articleTitle |
Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.
|
|
pubmed:affiliation |
Division of Medical Oncology, Istituto Nazionale Tumori, Milano, Italy.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|
